4D Molecular Therapeutics (FDMT) EBT Margin Growth (1y) (2021 - 2026)
4D Molecular Therapeutics (FDMT) EBT Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 452.00 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1,076.00 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -9,422.00 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -392.00 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1,911.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 29,565.00 |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 56.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.43 Mn |
| Mar 31, 2026 | 35.00 Mn |
| Dec 31, 2025 | 505.50 Mn |
| Sep 30, 2025 | 250.30 Mn |
| Jun 30, 2025 | 30.98 Mn |
| Mar 31, 2025 | -21.36 Mn |
| Dec 31, 2024 | -522.91 Mn |
| Sep 30, 2024 | -259.83 Mn |
| Jun 30, 2024 | -88.75 Mn |
| Mar 31, 2024 | -12.30 Mn |
| Dec 31, 2023 | 17.65 Mn |
| Sep 30, 2023 | 931,985.00 |
| Jun 30, 2023 | -32,662.00 |
| Mar 31, 2023 | -1.38 Mn |
| Dec 31, 2022 | 2.61 Mn |
| Sep 30, 2022 | -598,415.00 |
| Jun 30, 2022 | -2.11 Mn |
| Mar 31, 2022 | -56,957.00 |
| Dec 31, 2021 | -2.77 Mn |
| Sep 30, 2021 | -337,438.00 |